NASDAQ:ISTA - Ista Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ista Pharmaceuticals logoISTA Pharmaceuticals, Inc. (ISTA) is a commercial-stage, multi-specialty pharmaceutical company. The Company is engaged in developing, marketing and selling its own products in the United States and Puerto Rico. ISTA is a prescription eye care business in the United States and has an allergy drug franchise. ISTA manufactures its finished good products through third-party contracts. ISTA in-licenses or acquires new products and technologies to add to its internal development. Its products and product candidates seek to treat allergy and diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye and ocular and nasal allergies. It has four products available for sale in the United States and Puerto Rico: BROMDAY (bromfenac ophthalmic solution) 0.09%, BEPREVE (bepotastine besilate ophthalmic solution) 1.5%, ISTALOL (timolol maleate ophthalmic solution) 0.5% and VITRASE (hyaluronidase injection).

Receive ISTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ISTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:ISTA
CUSIPN/A
Phone+1-949-7886000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

Ista Pharmaceuticals (NASDAQ:ISTA) Frequently Asked Questions

What is Ista Pharmaceuticals' stock symbol?

Ista Pharmaceuticals trades on the NASDAQ under the ticker symbol "ISTA."

What is the consensus analysts' recommendation for Ista Pharmaceuticals?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ista Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Ista Pharmaceuticals been receiving favorable news coverage?

Media coverage about ISTA stock has been trending somewhat positive on Friday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ista Pharmaceuticals earned a media sentiment score of 0.02 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 45.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Ista Pharmaceuticals?

Shares of ISTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Ista Pharmaceuticals?

Ista Pharmaceuticals' mailing address is #D1, 10574 Acacia Street, RANCHO CUCAMONGA, CA 91730, United States. The specialty pharmaceutical company can be reached via phone at +1-949-7886000.


MarketBeat Community Rating for Ista Pharmaceuticals (NASDAQ ISTA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Ista Pharmaceuticals and other stocks. Vote "Outperform" if you believe ISTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.